Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin act⦠read more
Healthcare
Biotechnology
20 years
USD
Exclusive to Premium users
$53.01
Price+6.55%
$3.26
$6.343b
Mid
-
Premium
Premium
-14838.8%
EBITDA Margin-16244.7%
Net Profit Margin-15299.8%
Free Cash Flow Margin$85.738m
-50.2%
1y CAGR-36.0%
3y CAGR-20.4%
5y CAGR-$606.311m
-0.8%
1y CAGR-32.5%
3y CAGR-36.3%
5y CAGR-$5.11
+0.9%
1y CAGR-21.0%
3y CAGR-21.7%
5y CAGR-$368.720m
$1.226b
Assets$1.594b
Liabilities$858.058m
Debt70.0%
-1.6x
Debt to EBITDA-$440.477m
-1.2%
1y CAGR-32.5%
3y CAGR-2268.1%
5y CAGR